Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Conditions
Interventions
cyclosporine
vehicle of OTX-101
Locations
3
United States
Martel Eye Medical Group
Rancho Cordova, California, United States
Cincinnati Eye Institute
Edgewood, Kentucky, United States
Fifth Avenue Eye Associates
New York, New York, United States
Start Date
February 1, 2016
Primary Completion Date
November 1, 2016
Completion Date
December 1, 2016
Last Updated
August 29, 2022
NCT03925727
NCT03418259
NCT02845674
NCT01797822
NCT02665234
NCT03408015
Lead Sponsor
Sun Pharmaceutical Industries Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions